FMP
CARGO Therapeutics, Inc. Common Stock
CRGX
NASDAQ
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
4.02 USD
-0.08 (-1.99%)
Historical Prices
From:
To:
About
ceo
Mr. Anup Radhakrishnan
sector
Healthcare
industry
Biotechnology
website
https://cargo-tx.comexchange
NASDAQ
Description
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San M...
CIK
0001966494
ISIN
US14179K1016
CUSIP
14179K101
Address
1900 Alameda De Las Pulgas
Phone
650-379-6143
Country
US
Employee
167
IPO Date
Nov 13, 2023
Financial Statement
Earnings
CRGX Financial Summary
CIK
0001966494
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
14179K101
ISIN
US14179K1016
Country
US
Price
4.02
Beta
0.64
Volume Avg.
1.12M
Market Cap
185.13M
Shares
-
52-Week
3-25.45
DCF
0.78
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.08
P/B
-
Website
https://cargo-tx.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CRGX News
Stuart Mooney
Jan 30, 2025
Cargo Therapeutics, Inc. (NASDAQ:CRGX) Faces Significant Sto...
Cargo Therapeutics, Inc. (NASDAQ:CRGX) is a company involved in the development of innovative therapies. Recently, the company has been under scrutiny due to significant changes in its stock price and investor sentiment. As of January 30, 2025, Truist Financial's analyst Asthika Goonewardene set a price target of $7 for CRGX, while the stock was trading at $13.19. This target suggests a potential decrease of approximately 46.93%. The downgrade from a Buy to a Hold by Truist, as reported by TheF...
The Motley Fool
Aug 16, 2024
Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This...
The cancer-focused biotech published its second-quarter results. Its loss was much narrower than analysts had expected.
GlobeNewsWire
May 28, 2024
CARGO Therapeutics to Participate in Upcoming Investor Confe...
SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences.
Zacks Investment Research
May 22, 2024
What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock
CARGO Therapeutics, Inc. (CRGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research
May 22, 2024
Wall Street Analysts See a 56.26% Upside in CARGO Therapeuti...
The consensus price target hints at a 56.3% upside potential for CARGO Therapeutics, Inc. (CRGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MarketBeat
Jan 8, 2024
IPO watch 2024: Which new stocks will hit the market?
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.
GlobeNewsWire
Jan 3, 2024
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Hea...
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California.
InvestorPlace
Dec 11, 2023
3 New Stock Listings That Can Deliver Multibagger Returns
The U.S. IPO market has been relatively sluggish this year with 149 IPOs. At the same time, disappointing stories outnumbered businesses that created value.
